Here's a concise, retail-friendly summary: **1. Business Performance:** SeQuent Scientific & Viyash Life Sciences delivered strong Q2 FY26 results.

The combined entity reported revenues of ₹852.1 Cr, up 16% YoY, and EBITDA of ₹189 Cr, surging 76% YoY with margin expanding to 22.2%. SeQuent's standalone revenue grew 15% to ₹424 Cr, with PAT skyrocketing 200% to ₹19.6 Cr.

Viyash also performed well, posting ₹428.1 Cr revenue (+17.8% YoY) and PAT of ₹53.3 Cr. **2. Growth Drivers or Strategy:** Growth is driven by new product launches, an improved product mix, and cost optimization.

The ongoing merger with Viyash is unlocking benefits in manufacturing synergies, R&D, and customer leads.

Future strategy focuses on realizing these synergies and building new revenue streams. **3. Recent Developments:** The Viyash merger is nearing completion, with NCLT approval expected soon.

SeQuent expanded its global footprint with new product launches in Brazil and Mexico.

A new production block was commissioned, enhancing capacity.

Viyash ramped up regulatory filings and completed a US FDA EIR. **4. Key Financial Metrics:** * Q2 FY26 Combined Revenue: ₹852.1 Cr (+16% YoY) * Q2 FY26 Combined EBITDA: ₹189 Cr (+76% YoY), 22.2% margin * Net Debt to LTM EBITDA: 0.7x * SeQuent Q2 PAT: ₹19.6 Cr (+200% YoY) * Viyash Q2 PAT: ₹53.3 Cr **5. Management Commentary / Outlook:** Management highlighted the company's transformational journey, affirming healthy growth across key metrics.

The merged entity is well-positioned for future expansion, focusing on synergy benefits and accelerating existing and new business segments.